Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HSHL i am thinking we have a little shell play here, low floater
this is wtf moment, yesterday i wanted to add at 7 all day long and could not. today the chart is uptrending again and it goes to 7's .... i added at 9 today. but i guess when this goes to .01 to .10 a tick or two will not be an issue
the beginning of a new UT leg on its way now..
Good point, I did just read about last years run..hmm
Why the volume? news coming?
BZCN why the volume??
GM Rinse was over two ticks ago.....
Strong 7's I'll take it...
CLOSE ON 8
ADX indicators are getting closer and closer. Once the green touches the the red and continues north then you better have your seatbelts on...the chart looks amazing.
8's With this volume taking place we could easily see .001 today
Not bad for a Monday morning....
yes, SALES A noun: income (at invoice values) received for goods and services over some given period of time ...The SALE of 250,000 doses would be a good.
Now stratey (did you actually mean to write strateGy?) I am being a wise guy lol.
You mean sells to buys are 2x's. all I know it looks to me at support because i have been trying to buy more at .0009. If you are keeping track of b/S you must be a much better trader than me. Good luck to you on eiher side of the trade.
WOW. Nice news all, I am extremely excited with the news. Go HTDS. Good size buys too. On the other hand :( I know that not all on this board can feel that way. 250,000 doses could be a great order.
HARD TO TREAT DISEASE (NASDAQ:HTDS) Strong Uptrend
Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
Based on a pre-defined weighted trend formula for chart analysis, HTDS scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Monday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending June 20th
+30 New 3 Month High in June
+100 Total Score
ino.COM
Sorry to bring them up. We have a huge amount of shares and with these volumes it should go up. I am holding shares and I expect it to move too.
Is this the highest volume ever? For any stock? Even with cmkx I never saw 2.6 bil. wow..
hygn time to load up..
GM. HYGN is the one to watch. Chart is looking good.
GM all. Quite frankly and IMO with this share structure there is no reason to even consider a rs. And according to pinksheets.com share structure was already decreased back in Oct. 2008. The company has expanded its focus since then and is taking steps to make it a profitable growing concern. We must be patient and wait for the financials, more positive news and I also will add that the chart is looking mavvvvvelous. Positive posts for positive folks... have a great day all.
Estimated Market Cap
$7,317,745 as of Jun 16, 2009
Outstanding Shares
245,561,919 as of May 20, 2009
Authorized Shares
500,000,000 as of Apr 17, 2009
Number of Share Holders of Record
121 as of May 20, 2009
Float
211,068,147 as of May 20, 2009
mobrown are you in this stock? yes or no.... if you are then you have done some DD and you are here for a possible profit and if are not then you sound like a suttle basher.... I am in this stock at this time and i usually do not post.
This is about to explode to the upside. NO RS needed, this company does not have a huge amount of shares O/S or authorized. And it is generating revenues and soon it will have audited financials. It all good stuff..
GNTA on the move
Gnta reload, chart still looking sweet
GNTA reloaD
April 23, 2009 08:05 AM Eastern Daylight Time
Genta Announces Presentations for Two Lead Compounds, Genasense® and Tesetaxel, at 2009 Annual ASCO Meeting
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA.OB) announced today that data from clinical trials of the Company's late-stage compounds, Genasense® (oblimersen sodium) Injection and tesetaxel, will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29- June 2, 2009 in Orlando, FL.
Genta has now completed enrollment into AGENDA, the second of two large randomized Phase 3 trials of Genasense plus dacarbazine chemotherapy in patients with advanced melanoma. In parallel, the Company has also sponsored a pilot dose-ranging study in advanced melanoma using Genasense combined with different chemotherapy, including Temodar® (temozolomide; Schering Plough, Inc.) plus Abraxane® (paclitaxel protein-bound particles for injectable suspension) [albumin bound]; Abraxis Oncology, Inc.). This trial employs a new brief intravenous infusion schedule for Genasense, as well as a biomarker for targeting patient selection similar to that employed in AGENDA. At ASCO, results of long-term survival from this pilot non-randomized trial will be reported.
Genta has also sponsored a clinical and pharmacokinetic study of tesetaxel, a leading oral taxane in clinical development, in patients with advanced cancer who were treated at doses up to and including the maximally tolerated dose. Prior trials have employed tesetaxel dosed according to height and weight parameters (i.e., milligrams of drug per square meter of body surface area) that are difficult to precisely administer in clinical practice using an oral drug. At ASCO, dosing and pharmacokinetic data based on conversion of tesetaxel from weight-based to flat dosing (e.g., a prescribed single dose of 50 mg) will be presented. Titles, dates and times of these presentations appear below.
Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. (Abstract #9080). Monday June 1, 2009. Poster Session: Melanoma/Skin Cancer: 8 am-12 pm.
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered taxane. (Abstract #2510). Monday June 1, 2009. Poster Session: Developmental Therapeutics: 2-6 pm; Discussion Session: 5-6 pm.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
SAFE HARBOR
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:
the Company’s ability to obtain marketing and reimbursement approvals for its products from the U.S. Food and Drug Administration (“FDA”) and other regulatory or governmental authorities;
the safety and efficacy of the Company’s products or product candidates;
the Company’s assessment of its clinical trials;
the commencement and completion of clinical trials;
the Company’s ability to develop, manufacture, license and sell its products or product candidates;
the Company’s ability to enter into and successfully execute and maintain license and collaborative agreements;
the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.
Contacts
Genta Investor Relations
908-286-3980
info@genta.com
April 23, 2009 08:05 AM Eastern Daylight Time
Genta Announces Presentations for Two Lead Compounds, Genasense® and Tesetaxel, at 2009 Annual ASCO Meeting
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA.OB) announced today that data from clinical trials of the Company's late-stage compounds, Genasense® (oblimersen sodium) Injection and tesetaxel, will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29- June 2, 2009 in Orlando, FL.
Genta has now completed enrollment into AGENDA, the second of two large randomized Phase 3 trials of Genasense plus dacarbazine chemotherapy in patients with advanced melanoma. In parallel, the Company has also sponsored a pilot dose-ranging study in advanced melanoma using Genasense combined with different chemotherapy, including Temodar® (temozolomide; Schering Plough, Inc.) plus Abraxane® (paclitaxel protein-bound particles for injectable suspension) [albumin bound]; Abraxis Oncology, Inc.). This trial employs a new brief intravenous infusion schedule for Genasense, as well as a biomarker for targeting patient selection similar to that employed in AGENDA. At ASCO, results of long-term survival from this pilot non-randomized trial will be reported.
Genta has also sponsored a clinical and pharmacokinetic study of tesetaxel, a leading oral taxane in clinical development, in patients with advanced cancer who were treated at doses up to and including the maximally tolerated dose. Prior trials have employed tesetaxel dosed according to height and weight parameters (i.e., milligrams of drug per square meter of body surface area) that are difficult to precisely administer in clinical practice using an oral drug. At ASCO, dosing and pharmacokinetic data based on conversion of tesetaxel from weight-based to flat dosing (e.g., a prescribed single dose of 50 mg) will be presented. Titles, dates and times of these presentations appear below.
Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. (Abstract #9080). Monday June 1, 2009. Poster Session: Melanoma/Skin Cancer: 8 am-12 pm.
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered taxane. (Abstract #2510). Monday June 1, 2009. Poster Session: Developmental Therapeutics: 2-6 pm; Discussion Session: 5-6 pm.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
SAFE HARBOR
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:
the Company’s ability to obtain marketing and reimbursement approvals for its products from the U.S. Food and Drug Administration (“FDA”) and other regulatory or governmental authorities;
the safety and efficacy of the Company’s products or product candidates;
the Company’s assessment of its clinical trials;
the commencement and completion of clinical trials;
the Company’s ability to develop, manufacture, license and sell its products or product candidates;
the Company’s ability to enter into and successfully execute and maintain license and collaborative agreements;
the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.
Contacts
Genta Investor Relations
908-286-3980
info@genta.com
news dissemination
Volume is picking up faST
We are about to bust out guys
SPNG is about to bust out
Good morning all. Sooner than later the PPS will go up, it has to, there's no way that it can stay below what it's worth. Maybe theres no insight in my statement but it was overbought, there had to be profit taking and now it is at a support much needed to sustain another rally. Just my huble view. We have a real company with a real product that is selling.
siri breaks .18 & itll fly
siri is in play boys and girls
Nice close. This is primed for a higher pps